Renalytix (RENX): Placing of 40% of the market value
This situation live
RENX Renalytix
1 Sep 2026 · announced · +0% on the day · +0% until the next step
The Company intends to raise a minimum of approximately £9.5 million gross proceeds through a placing and a subscription of new ordinary shares.
3 Sep 2026 · announced · +0% on the day · +30% until the next step
The Placing Price represents a premium of approximately 44.6 per cent. to the mid-market closing price of 4.15 pence per Ordinary Share on 28 August 2026.
3 Sep 2026 · completed · +0% on the day · +30% until the next step
This Fundraise has significantly strengthened our balance sheet and allows us to pivot our operations to support national access and logistics with our new collaborator, Quest Diagnostics, for kidneyi
Placing of 40% of the market value
completed · completed
RaisePlacing · £10.1 million
Of market value40.3%
Reaction on the day+30%
As of 8 Sep 2026 ↗
Since Oct 2023: 301 situations of this kind – completed 77%, went quiet 23%; median share price -17% six months after they opened
Every step · 4
- 1 Sep 2026 announced · +0% on the day – The Company intends to raise a minimum of approximately £9.5 million gross proceeds through a placing and a subscription of new ordinary shares. ↗
- 3 Sep 2026 announced · +0% on the day – The Placing Price represents a premium of approximately 44.6 per cent. to the mid-market closing price of 4.15 pence per Ordinary Share on 28 August 2026. ↗
- 3 Sep 2026 completed · +0% on the day – This Fundraise has significantly strengthened our balance sheet and allows us to pivot our operations to support national access and logistics with our new... ↗
- 8 Sep 2026 completed – the Company has raised aggregate gross proceeds of £380,142.12, in addition to the £10.1 million gross proceeds raised through the Placing and Subscription ↗
What is happening
Renalytix: Placing of 40% of the market value – completed. ['completed']
- In short
- Renalytix launched a bookbuild on 1 September 2026 at 6p, a premium to the market price. It funds the Quest Diagnostics rollout and converts the Heights bonds to equity. The bookbuild closed oversubscribed with £10.1m raised, and Heights holds no debt claim. A WRAP retail offer of up to £1.0m at 6p now opens, closing 7 September. The second tranche needs a General Meeting.
- Announced
- 1 Sep 2026 · announced · +0% on the day
- Latest
- 8 Sep 2026 · completed · +30% on the day
- Size
- £10.1m gross placing at 6p; up to £1.0m WRAP Retail Offer
- Shares
- 168,366,151 new shares plus 57,729,741 Conversion Shares to Heights
- First tranche
- 109,082,253 Placing Shares plus 57,729,741 Conversion Shares; admission 8 September 2026
- Second tranche
- Second Tranche Placing, Subscription and Retail Offer Shares; needs General Meeting; admission about 29 September 2026
- Insiders
- Directors and PDMRs subscribed US$303,366 in total; 6-month lock-in
- Price
- 6p, a 44.6% premium to the 4.15p close on 28 August 2026
- Retail offer
- Up to 16,666,666 shares; minimum £100; closes 4:00 p.m. on 7 September 2026
From the company's own announcements. Not investment advice.
Briefing Pro
New to Renalytix? Get up to speed in 2 minutes.
What it does, how it got here, what management promised and delivered – written from its own announcements.
Get the RENX briefing →Also at Renalytix 3 open
Insider conviction1 director buying – £70k in 1 buy
Transformational contract / build-outStrategic partnerships and EMR rollout – Funding secured; interface build pending
Project milestonesTwo-year outcomes data and CE marking – Submitted for publication; CE review progressing
Upgrade / downgrade cycleResults below expectations – below expectations · closed
Dilutive fundraisePlacing of 138% of the market value – completed · closed
Renalytix – company page →